November 18th, 2026Low CRC Incidence Found After Endoscopic Mucosal ResectionCRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.Read more
November 18th, 2026FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMRThe FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.Read more
November 17th, 2026Real-World Data Support Cemiplimab Efficacy in Advanced NSCLCIn this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.Read more
November 17th, 2026FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLCNeladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.Read more
November 16th, 2026Shorter US Residence Linked to Greater CRC Screening NonadherenceNon-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.Read more
November 16th, 2026FDA Approves Weekly Gefurulimab for Generalized Myasthenia GravisThe once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.Read more
November 19th, 2026Iron Deficiency in Heart Failure Is a Workflow Problem, Faculty SayFaculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.Read more
November 19th, 2026FDA Approves First siRNA Therapy for AChR-Positive Myasthenia GravisThe FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.Read more